The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2018 | Combination therapies in CLL: ibrutinib and venetoclax
There has been a multitude of novel, exciting therapies within the field of chronic lymphocytic leukemia (CLL), explains Stephen Devereux, FRCP, FRCPath, PhD, of King’s College Hospital NHS Foundation Trust, London, UK. At the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK, Prof. Devereux discusses the CLARITY trial (ISCRTN13751862), exploring a combination of ibrutinib and venetoclax, and the promise that this may in the future result in a curative therapy for certain patients.
